Építés alatt – nem éles oldal
Belépés

NCT07429214Fut, nem toboroz

A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF

Workflow Study of the VARIPULSE™ Catheter With the TRUPULSE™ Generator for Treatment of Paroxysmal Atrial Fibrillation (PAF) or Persistent Atrial Fibrillation (PsAF) With the New VARIPULSE™ Pro Software

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. nov. 4.

Következő lépések

Rövid összefoglaló (regiszter, angolul)

The main purpose of this clinical study is to investigate the effectiveness workflow of the clinical use of the pulsed field (PF) ablation system (VARIPULSE™ Catheter and TRUPULSE™ Generator) when used for cardiac ablation with the new VARIPULSE™ Pro software in participants with paroxysmal atrial fibrillation (PAF; irregular heartbeat where episodes start and stop on their own, usually within seven days) and persistent atrial fibrillation (PsAF; irregular, rapid heartbeat that lasts over 7 days up to 1year and doesn't stop on its own).

Állapot (regiszter)
Fut, nem toboroz
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
42 (tényleges)
Első benyújtás
2026. febr. 18.
Kezdés
2026. márc. 23.
Elsődleges befejezés
2026. dec. 30.
Fő szponzor
Biosense Webster, Inc.
NCT-szám
NCT07429214

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó
  • Bevont résztvevők: 42
  • 2026. márc. 23. és az elsődleges befejezés (2026. dec. 30.) között
  • 6 helyszín, 5 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • Previous surgical or catheter ablation for atrial fibrillation
  • Any cardiac surgery within the past 2 months (60 days prior to consent date) (includes percutaneous coronary intervention [PCI])
  • Previous coronary artery bypass grafting (CABG) in conjunction with valvular surgery, cardiac surgery (for example, ventriculotomy, atriotomy) or valvular cardiac (surgical or percutaneous) procedure
  • Prior diagnosis of pulmonary vein stenosis
  • Myocardial infarction (MI) within the past 2 months (60 days prior to consent date)
  • Documented thromboembolic event (including transient ischemic attack [TIA]) within the past 6 months [180 days prior to consent date])
  • Unstable angina pectoris within the past 6 months prior to consent date
  • Current enrollment in an investigational study evaluating another device, biologic, or drug
  • Categorized as vulnerable population and requiring special treatment with respect to safeguards of well-being

Más betegség

  • History of blood clotting, bleeding abnormalities or contraindication to anticoagulation (heparin, warfarin, or dabigatran)
  • Rheumatic Heart Disease
  • Uncontrolled heart failure or New York heart association (NYHA) function class III or IV
  • Anticipated cardiac transplantation, cardiac surgery, or other major surgery within the next 12 months
  • Acute illness or active systemic infection or sepsis
  • Presence of any other condition that precludes appropriate vascular access (such as inferior vena cava [IVC] filter)
  • Significant pulmonary disease, (for example, restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease [COPD]) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms
  • Contraindication for MRI such as use of contrast agents due to advanced renal disease, claustrophobia, implantable pacemakers, implantable cardioverter/defibrillators (ICDs),etc. (at principal investigator [PI] discretion)

Laborértékek

  • Severely compromised left ventricular ejection fraction (LVEF less than [<] 40 percent [%])
  • Previously known AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause (for example, documented obstructive sleep apnea, acute alcohol toxicity, morbid obesity [Body Mass Index >40 kilogram per meter square {kg/m\^2}], renal insufficiency (with an estimated creatinine clearance < 30 milliliters per minute {mL/min}/1.73 m\^2)

Életkor

  • Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of childbearing age and plan on becoming pregnant during the course of the clinical investigation

Egyéb

  • Continuous AF greater than (>) 12 months (1-Year) (Longstanding Persistent AF)
  • Any carotid stenting or endarterectomy
  • Presence of left atrium (LA) thrombus
  • Severe dilatation of the LA (left atrial diameter [LAD] >50 millimeters [mm] antero-posterior diameter in case of transthoracic echocardiography [TTE])
  • Known significant pulmonary vein (PV) anomaly that in the opinion of the investigator would preclude enrollment in this study
  • Pre-existing hemi diaphragmatic paralysis
  • Severe mitral regurgitation
  • Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch, prosthetic valve or other abnormality that precludes catheter introduction or manipulation
  • Presence of intramural thrombus, tumor or other abnormality that precludes vascular access, or manipulation of the catheter
  • Significant congenital anomaly or medical problems that in the opinion of the investigator would preclude enrollment in this study
  • Presenting contra-indications for the devices used in the study, as indicated in the respective instructions for use (IFU)
  • Life expectancy less than 12 months
  • Presence of iron-containing metal fragments in the body
  • Unresolved pre-existing neurological deficit

Kiket keres a vizsgálat

  • Diagnosed with symptomatic persistent atrial fibrillation (PsAF) or paroxysmal atrial fibrillation (PAF)
  • Selected to undergo an ablation procedure for management of their arrhythmia by pulmonary vein isolation (PVI) only or PVI only with cavotricuspid isthmus (CTI) dependent atrial flutter ablation
  • Failed at least one antiarrhythmic drug (AAD; class I to IV) as evidenced by recurrent symptomatic atrial fibrillation (AF), or intolerable or contraindicated to the AAD
  • Age 18-75 years
  • Willing and capable of providing consent
  • Able and willing to comply with all pre-, post- and follow-up testing and requirements

Életkor a regiszterben: 18 év – 75 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (6)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
AZORG Campus Aalst-MoorselbaanAalstBelgiumIsmeretlen állapot
A.Z. Sint JanBrugesBelgiumIsmeretlen állapot
University Hospital of the Ruhr-University of BochumBad OeynhausenNémetországIsmeretlen állapot
Aarhus University HospitalAarhus NDániaIsmeretlen állapot
IRCCS Policlinico San DonatoSan Donato MilaneseOlaszországIsmeretlen állapot
Vilnius University Hospital Santaros ClinicsVilniusLitvániaIsmeretlen állapot

Te vagy a koordinátor? Erősítsd meg az adatokat

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.